Tom 2, Nr 3-4 (2022)
STANOWISKO EKSPERTÓW
Opublikowany online: 2023-03-06
Wyświetlenia strony
393
Wyświetlenia/pobrania artykułu
147
Mutacje genu IDH1 — stanowisko ekspertów
Hematologia - Edukacja 2022;2(3-4):113-124.
Streszczenie
Iwosydenib jest silnym — stosowanym doustnie — inhibitorem szlaku zależnego od IDH1. Przedkliniczne dowody wartości iwosydenibu zostały potwierdzone przez wyniki prospektywnych badań klinicznych u chorych na ostrą białaczkę szpikową i raka dróg żółciowych z mutacją w genie IDH1. Optymalne wykorzystanie iwosydenibu — podobnie do innych ukierunkowanych leków przeciwnowotworowych — zależy od sprawnej i dokładnej diagnostyki morfologicznej i molekularnej. Artykuł został przygotowany w celu przedstawienia obecnych metod oceny stanu genu IDH1 i naukowego uzasadnienia dla stosowania iwosydenibu w ostrej białaczce szpikowej oraz raku dróg żółciowych.
Słowa kluczowe: gen IDH1ostra białaczka szpikowarak dróg żółciowychleczenie ukierunkowane molekularnieiwosydenib
Referencje
- Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol. 2018; 14(10): 979–993.
- Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019; 10(4): 751–765.
- Obwieszczenie Ministra Zdrowia z dnia 24 września 2021 r. w sprawie standardów akredytacyjnych w zakresie udzielania świadczeń zdrowotnych oraz funkcjonowania jednostek diagnostyki patomorfologicznej. (Dz. Urz. Min. Zdr. 2021 r., poz. 75). http://dziennikmz.mz.gov.pl/DUM_MZ/2021/75/oryginal/akt.pdf (September 24, 2021).
- Akredytacja w patomorfologii. https://zdrowie.gov.pl/power/strona-1001-akredytacja_w_patomorfologii.html (March 14, 2022).
- Podręcznik wdrożeniowy. Wdrażanie standardów akredytacyjnych w jednostkach diagnostyki patomorfologicznej. Wskazówki i zalecenia. CMJ, Kraków 2022.
- Rozporządzenie Ministra Zdrowia z dnia 18 grudnia 2017 r. w sprawie standardów organizacyjnych opieki zdrowotnej w dziedzinie patomorfologii. https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20170002435 (December 12, 2017).
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12): 1345–1377.
- Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23): 2209–2221.
- Cerchione C, Romano A, Daver N, et al. IDH1/IDH2 Inhibition in acute myeloid leukemia. Front Oncol. 2021; 11: 639387.
- Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018; 24(7): 1015–1023.
- Xu Q, Li Y, Lv Na, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res. 2017; 23(15): 4511–4522.
- Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018; 9(4): 300–305.
- DiNardo CD, Stein EM, Botton Sde, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018; 378(25): 2386–2398.
- Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020; 135(7): 463–471.
- Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022; 386(16): 1519–1531.
- Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11): 1200–1228.
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12): 1345–1377.
- Grimwade D, Hills RK, Moorman AV, et al. National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354–365.
- Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010; 24(7): 1302–1309.
- Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010; 116(12): 2122–2126.
- Libura M, Bialopiotrowicz E, Giebel S, et al. IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Sci Rep. 2021; 11(1): 10017.
- Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021; 7(11): 1669–1677.
- Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022; 27(5): 100737.
- Abou-Alfa GK, Macarulla T, Javle M, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(6): 796–807.
- Lowery MA, Burris HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019; 4(9): 711–720.
- Rimini M, Burgio V, Antonuzzo L, et al. Real-world dta on ivosidenib in patients with previously treated isocitrate dehydrogenase 1-mutated intrahepatic cholangiocarcinomas: an early exploratory analysis. Target Oncol. 2022; 17(5): 591–596.
- Normanno N, Martinelli E, Melisi D, et al. Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open. 2022; 7(3): 100505.
- Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018; 24(17): 4154–4161.
- Silverman IM, Hollebecque A, Friboulet L, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 2021; 11(2): 326–339.
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatobiliary cancers v3. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf (October, 2022).
- Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31(11): 1491–1505.
- Pellino A, Loupakis F, Cadamuro M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018; 3: 40.
- Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021; 32(9): 1111–1126.
- Simbolo M, Fassan M, Ruzzenente A, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014; 5(9): 2839–2852.
- Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012; 43(10): 1552–1558.
- Simbolo M, Vicentini C, Ruzzenente A, et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep. 2018; 8(1): 7119.
- Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 2018; 34(2): 186–195.
- De Luca A, Esposito Abate R, Rachiglio AM, et al. FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention. Int J Mol Sci. 2020; 21(18).
